These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 34225439)

  • 1. [Immune checkpoint inhibitors in the treatment and management of hepatocellular carcinoma-related adverse reactions].
    Li ZC; Ren ZG
    Zhonghua Gan Zang Bing Za Zhi; 2021 Jun; 29(6):600-603. PubMed ID: 34225439
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment with pembrolizumab after hypersensitivity reaction to nivolumab in a patient with hepatocellular carcinoma.
    Choi B; McBride A; Scott AJ
    Am J Health Syst Pharm; 2019 Oct; 76(21):1749-1752. PubMed ID: 31612928
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acute-onset diabetes mellitus with ketoacidosis in a nivolumab-treated patient with hepatocellular carcinoma.
    Harsch IA; Konturek PC
    Wiad Lek; 2018; 71(5):945-948. PubMed ID: 30176620
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Review article: immune checkpoint inhibitors and the liver, from therapeutic efficacy to side effects.
    Lombardi A; Mondelli MU
    Aliment Pharmacol Ther; 2019 Oct; 50(8):872-884. PubMed ID: 31378985
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dual immune checkpoint blockade in hepatocellular carcinoma: where do we stand?
    Carloni R; Rizzo A; Ricci AD; Frega G; Federico AD; Palloni A; Marco MD; Gadaleta-Caldarola G; Brandi G
    Future Oncol; 2022 Mar; 18(8):1023-1034. PubMed ID: 35109664
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial.
    El-Khoueiry AB; Sangro B; Yau T; Crocenzi TS; Kudo M; Hsu C; Kim TY; Choo SP; Trojan J; Welling TH; Meyer T; Kang YK; Yeo W; Chopra A; Anderson J; Dela Cruz C; Lang L; Neely J; Tang H; Dastani HB; Melero I
    Lancet; 2017 Jun; 389(10088):2492-2502. PubMed ID: 28434648
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The safety and efficacy of lenvatinib combined with immune checkpoint inhibitors therapy for advanced hepatocellular carcinoma.
    Wang Y; Jiang M; Zhu J; Qu J; Qin K; Zhao D; Wang L; Dong L; Zhang X
    Biomed Pharmacother; 2020 Dec; 132():110797. PubMed ID: 33068935
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunotherapy for hepatocellular carcinoma: A review of potential new drugs based on ongoing clinical studies as of 2019.
    Tovoli F; Casadei-Gardini A; Benevento F; Piscaglia F
    Dig Liver Dis; 2019 Aug; 51(8):1067-1073. PubMed ID: 31208929
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunotherapy for advanced hepatocellular carcinoma: a focus on special subgroups.
    Pinter M; Scheiner B; Peck-Radosavljevic M
    Gut; 2021 Jan; 70(1):204-214. PubMed ID: 32747413
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Chinese multidisciplinary expert consensus on combined immunotherapy based on immune checkpoint inhibitors for hepatocellular carcinoma(2021 version)].
    ; ;
    Zhonghua Gan Zang Bing Za Zhi; 2021 Jul; 29(7):636-647. PubMed ID: 34371534
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatotoxicity From Immune Checkpoint Inhibitors: A Systematic Review and Management Recommendation.
    Peeraphatdit TB; Wang J; Odenwald MA; Hu S; Hart J; Charlton MR
    Hepatology; 2020 Jul; 72(1):315-329. PubMed ID: 32167613
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fatal hepatic necrosis after nivolumab as a bridge to liver transplant for HCC: Are checkpoint inhibitors safe for the pretransplant patient?
    Nordness MF; Hamel S; Godfrey CM; Shi C; Johnson DB; Goff LW; O'Dell H; Perri RE; Alexopoulos SP
    Am J Transplant; 2020 Mar; 20(3):879-883. PubMed ID: 31550417
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nivolumab for the treatment of hepatocellular carcinoma.
    Finkelmeier F; Waidmann O; Trojan J
    Expert Rev Anticancer Ther; 2018 Dec; 18(12):1169-1175. PubMed ID: 30304963
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Severe terminal ileitis induced by single-agent nivolumab administered every four weeks.
    Dasanu CA; Plaxe SC; Gupta V; Popescu IM; Grover M; Alvarez-Argote J
    J Oncol Pharm Pract; 2020 Sep; 26(6):1516-1519. PubMed ID: 32028838
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunostimulatory monoclonal antibodies for hepatocellular carcinoma therapy. Trends and perspectives.
    Mazzolini GD; Malvicini M
    Medicina (B Aires); 2018; 78(1):29-32. PubMed ID: 29360073
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sarcoidosis-like reaction induced by immune checkpoint inhibitor in a patient with hepatocellular carcinoma: a case report.
    Torres-Zurita A; Vázquez-Montero L; Gallego-López L; Mediano-Rambla MD; de la Cruz-Merino L
    Front Immunol; 2023; 14():1150128. PubMed ID: 37781378
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular targeted and immune checkpoint therapy for advanced hepatocellular carcinoma.
    Liu Z; Lin Y; Zhang J; Zhang Y; Li Y; Liu Z; Li Q; Luo M; Liang R; Ye J
    J Exp Clin Cancer Res; 2019 Nov; 38(1):447. PubMed ID: 31684985
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Resolution of a hepatoduodenal fistula after nivolumab treatment in a patient with hepatocellular carcinoma: challenges in immunotherapy.
    De Somer T; Vanderstraeten E; Bouderez V; Monsaert E; Van Steenkiste C
    Acta Clin Belg; 2022 Feb; 77(1):108-112. PubMed ID: 32529925
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emerging role of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma.
    Longo V; Brunetti O; Gnoni A; Licchetta A; Delcuratolo S; Memeo R; Solimando AG; Argentiero A
    Medicina (Kaunas); 2019 Oct; 55(10):. PubMed ID: 31627433
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Immunotherapy clinical application and research prospects for liver cancer].
    Xia F; Chen XP
    Zhonghua Gan Zang Bing Za Zhi; 2021 Jul; 29(7):615-617. PubMed ID: 34371529
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.